Last reviewed · How we verify
Urinary-hCG
Urinary-hCG is a human chorionic gonadotropin (hCG) derived from urine that stimulates hormone production in reproductive tissues.
Urinary-hCG is a human chorionic gonadotropin (hCG) derived from urine that stimulates hormone production in reproductive tissues. Used for Hypogonadism in males, Infertility associated with hypogonadotropic hypogonadism, Ovulation induction in females with infertility.
At a glance
| Generic name | Urinary-hCG |
|---|---|
| Also known as | Profasi |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | Gonadotropin |
| Target | Luteinizing hormone receptor (LH-R) |
| Modality | Small molecule |
| Therapeutic area | Reproductive/Endocrinology |
| Phase | Phase 3 |
Mechanism of action
This is a naturally-derived gonadotropin extracted and purified from the urine of pregnant women. It acts as a luteinizing hormone (LH) analog, binding to LH receptors on Leydig cells in males and theca cells in females to stimulate testosterone and progesterone production respectively. It is used clinically to support reproductive function and hormone replacement.
Approved indications
- Hypogonadism in males
- Infertility associated with hypogonadotropic hypogonadism
- Ovulation induction in females with infertility
Common side effects
- Injection site reactions
- Headache
- Mood changes
- Ovarian hyperstimulation syndrome (OHSS) in females
Key clinical trials
- PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis (PHASE1)
- Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female Runners (NA)
- Multimodal Cardiovascular and Hepatic Population Imaging
- Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol
- LE + CC vs. LE for Ovulation Induction (NA)
- UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients (PHASE1)
- Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?
- Continuous Double Ovarian Stimulation. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Urinary-hCG CI brief — competitive landscape report
- Urinary-hCG updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI